Safety and Efficacy of Ledipasvir/Sofosbuvir in Adults With Chronic HCV Infection
Status:
Completed
Trial end date:
2016-06-30
Target enrollment:
Participant gender:
Summary
The primary objectives of this study are to evaluate the antiviral efficacy, safety, and
tolerability of ledipasvir/sofosbuvir (LDV/SOF) fixed dose combination (FDC) with or without
ribavirin (RBV) in adults with chronic hepatitis C virus (HCV) infection.
Phase:
Phase 3
Details
Lead Sponsor:
Gilead Sciences
Treatments:
Ledipasvir Ledipasvir, sofosbuvir drug combination Sofosbuvir